Background: Aim of the study was to compare efficacy of Tadalafil and Alfuzosin regimens in patients of Benign Prostate Hyperplasia.Methods: It was a comparative, prospective, observational, non-invasive, parallel and randomised study conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. 60 patients diagnosed with Benign Prostate Hyperplasia along with Lower Urinary Tract Symptoms, out which, 30 patients, consuming Tadalafil and 30 patients consuming Alfuzosin were considered. History regarding the concerned disease and the compliance of treatment was taken. Symptom scores were assessed with the help of International Prostate Symptom Score, Quality of Lifestyle Score and Erectile Dysfunction Score. Physical examinat...
Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodies...
Background: Benign prostate hyperplasia (BPH) is the most common pathological condition that contrib...
To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulat...
Objectives: This study was done to determine the efficacy of alpha-1 adrenoceptor blockers like...
Background: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quali...
Introduction: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often result...
Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antago...
Background: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS)...
Background: Benign prostatic hyperplasia (BPH) is usually seen in men above 45 years. α-blockers (al...
Objective: Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate associat...
Introduction: Tadalafil and Tamsulosin have both been approved for use in the management of lower ur...
Epidemiological data link erectile dysfunction (ED) and benign prostatic hyperplasia (BPH)-associate...
INTRODUCTION : Benign prostatic hyperplasia (BPH), one of the most common diseases of aging men, ca...
Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical...
Background: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hy...
Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodies...
Background: Benign prostate hyperplasia (BPH) is the most common pathological condition that contrib...
To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulat...
Objectives: This study was done to determine the efficacy of alpha-1 adrenoceptor blockers like...
Background: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quali...
Introduction: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often result...
Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antago...
Background: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS)...
Background: Benign prostatic hyperplasia (BPH) is usually seen in men above 45 years. α-blockers (al...
Objective: Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate associat...
Introduction: Tadalafil and Tamsulosin have both been approved for use in the management of lower ur...
Epidemiological data link erectile dysfunction (ED) and benign prostatic hyperplasia (BPH)-associate...
INTRODUCTION : Benign prostatic hyperplasia (BPH), one of the most common diseases of aging men, ca...
Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical...
Background: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hy...
Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodies...
Background: Benign prostate hyperplasia (BPH) is the most common pathological condition that contrib...
To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulat...